Correlation of the severity of coronary artery disease with patients' metabolic profile- rationale, design and baseline patient characteristics of the CorLipid trial

BMC Cardiovascular Disorders

Anastasios Papadopoulos¹  Georgios Theodoridis²  Andreas S. Papazoglou³  Nikolaos Stalikas³  Dimitrios V. Moysidis³  Haralambos Karvounis³  Georgios Sofidis³  Efstratios Karagiannidis³  Anastasios Kartas³  Georgios Sianos³  Leandros Stefanopoulos⁴  Eleftherios Panteris⁵  Olga Deda⁵  Helen Gika⁵ 

[1] 1St Propaedeutic Internal Medicine Department, AHEPA Hospital Aristotle University of Thessaloniki, Thessaloniki, Greece;Biomic_AUTh, CIRI-AUTH Center for Interdisciplinary Research and Innovation Aristotle University of Thessaloniki, 57001, Thessaloniki, Greece;Laboratory of Analytical Chemistry, Department of Chemistry, Aristotle University of Thessaloniki, Thessaloniki, Greece;First Department of Cardiology, AHEPA University Hospital, Aristotle University of Thessaloniki, St. Kiriakidi 1, 54636, Thessaloniki, Greece;Lab of Computing, Medical Informatics and Biomedical Imaging Technologies, Aristotle University of Thessaloniki, 54124, Thessaloniki, Greece;Laboratory of Forensic Medicine and Toxicology, School of Medicine, Aristotle University of Thessaloniki, 54124, Thessaloniki, Greece;Biomic_AUTh, CIRI-AUTH Center for Interdisciplinary Research and Innovation Aristotle University of Thessaloniki, 57001, Thessaloniki, Greece;

关键词: Metabolomics;    Metabolic profile;    Ceramides;    Carnitines;    Biomarkers;    Coronary artery disease;    SYNTAX score;    Atherosclerosis;    Acute coronary syndrome;    PCI;   

DOI  :  10.1186/s12872-021-01865-2

来源: Springer

【 摘 要 】

BackgroundCoronary artery disease (CAD) remains one of the leading causes of mortality and morbidity worldwide. As oxygen and nutrient supply to the myocardium significantly decrease during ischemic periods, important changes occur regarding myocardial intermediary energy metabolism. Metabolomics is an emerging field in systems biology, which quantifies metabolic changes in response to disease progression. This study aims to evaluate the diagnostic utility of plasma metabolomics-based biomarkers for determining the complexity and severity of CAD, as it is assessed via the SYNTAX score.MethodsCorlipid is a prospective, non-interventional cohort trial empowered to enroll 1065 patients with no previous coronary intervention history, who undergo coronary angiography in University Hospital AHEPA, Thessaloniki. Venous blood samples are collected before coronary angiography. State-of the-art analytical methods are performed to calculate the serum levels of novel biomarkers: ceramides, acyl-carnitines, fatty acids, and proteins such as galectin-3, adiponectin, and the ratio of apolipoprotein B/apolipoprotein A1. Furthermore, all patients will be categorized based on the indication for coronary angiography (acute coronary syndrome, chronic coronary syndrome, preoperative coronary angiography) and on the severity of CAD using the SYNTAX score. Follow-up of 12 months after enrollment will be performed to record the occurrence of major adverse cardiovascular events. A risk prediction algorithm will be developed by combining clinical characteristics with established and novel biomarkers to identify patients at high risk for complex CAD based on their metabolite signatures. The first patient was enrolled in July 2019 and completion of enrollment is expected until May 2021.DiscussionCorLipid is an ongoing trial aiming to investigate the correlation between metabolic profile and complexity of coronary artery disease in a cohort of patients undergoing coronary angiography with the potential to suggest a decision-making tool with high discriminative power for patients with CAD. To our knowledge, Corlipid is the first study aspiring to create an integrative metabolomic biomarkers-based algorithm by combining metabolites from multiple classes, involved in a wide range of pathways with well-established biochemical markers.Trial registration CorLipid trial registration: ClinicalTrials.gov number: NCT04580173. Registered 8 October 2020—Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT04580173.

【 授权许可】

CC BY